General Information of Drug (ID: DM4H7D5)

Drug Name
PHA-767491 Drug Info
Synonyms
PHA-767491; 845714-00-3; PHA 767491; CAY10572(PHA-767491); PHA-767491 (CAY10572); 2-Pyridin-4-yl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one; 1,5,6,7-Tetrahydro-2-(4-pyridinyl)-4H-pyrrolo[3,2-c]pyridin-4-one; Pyrrolopyridinone, 1; Cdc7/Cdk9 Inhibitor; Kinome_2973; JMC502647 Compound 8; MLS006011036; SCHEMBL4767679; GTPL8763; CHEMBL225519; CTK8F8505; CHEBI:95058; BDBM27344; DTXSID50471069; MolPort-009-019-436; HMS3656P19; HMS3229B21; BCP02855; PHA-767491A; PHA767491; ZINC16052718; s2742; 2651AH; AKOS026674124; SB19465; CS-1208
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11715767
ChEBI ID
CHEBI:95058
CAS Number
CAS 845714-00-3
TTD Drug ID
DM4H7D5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug(s) Targeting CDC7-related kinase (CDC7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-863233 DM5HUY8 Haematological malignancy 2B33.Y Phase 1/2 [2]
TAK-931 DM1ALY9 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PMID26161698-Compound-44 DM8UPO3 N. A. N. A. Patented [4]
PMID19115845C89S DMB9F2L Discovery agent N.A. Investigative [5]
PMID20873740C18 DMVHR3Z Discovery agent N.A. Investigative [6]
PMID24793884C74 DMFSJQC Discovery agent N.A. Investigative [7]
PMID24793884C77 DMZENGX Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CDC7-related kinase (CDC7) TTSMTDI CDC7_HUMAN Modulator [1]

References

1 Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64.
2 Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
5 First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
6 Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
7 Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.